8-KLeadership ChangesExhibits & Filings

GILEAD SCIENCES, INC. 8-K Report, Executive Changes (Aug 5, 2008)

Filed August 5, 2008For Securities:GILD

Summary

This 8-K filing from Gilead Sciences, Inc. (GILD) on August 5, 2008, primarily announces the appointment of Richard J. Whitley, MD, to its Board of Directors, effective July 30, 2008. Dr. Whitley, who previously served on the company's Scientific Advisory Board since 2003, will also continue his role on the Scientific Committee of the Board. His appointment is expected to strengthen the company's scientific expertise at the directorial level. The filing also details Dr. Whitley's compensation for his new role, which includes stock options and a prorated annual cash retainer. This appointment signals Gilead's ongoing commitment to leveraging scientific talent and advisory input to guide its strategic direction, particularly in its research and development efforts.

Key Highlights

  • 1Richard J. Whitley, MD, appointed to the Board of Directors, effective July 30, 2008.
  • 2Dr. Whitley will serve on the Board's Scientific Committee.
  • 3Dr. Whitley previously served on Gilead's Scientific Advisory Board from 2003 to July 30, 2008.
  • 4Dr. Whitley will continue to serve on the Scientific Advisory Board but will no longer be compensated for that role.
  • 5Compensation for Dr. Whitley's director role includes a grant of 30,000 stock options.
  • 6Dr. Whitley will receive a prorated annual cash retainer of $55,232.88.
  • 7A press release announcing Dr. Whitley's election is attached as Exhibit 99.1.

Frequently Asked Questions

Richard J. Whitley, MD, has been appointed to the Board of Directors, effective July 30, 2008. He will also serve on the Board's Scientific Committee.

Dr. Whitley has been a member of Gilead's Scientific Advisory Board since 2003, indicating a deep understanding of the company's scientific endeavors. His new role on the Board's Scientific Committee will leverage this expertise at a higher governance level.

Dr. Whitley will receive a grant of 30,000 stock options under the Company's 2004 Equity Incentive Plan and a prorated annual cash retainer of $55,232.88 for his service on the Board.

While this filing focuses on a directorial appointment, the addition of a director with a strong scientific background, particularly on the Scientific Committee, suggests a continued emphasis on research and development and a commitment to informed scientific oversight at the board level.